Concurrent chemoradiotherapy for limited small-cell lung cancer.
Publication/Presentation Date
9-1-1997
Abstract
It is now established that the treatment of choice for limited small-cell lung cancer (SCLC) in the United States, Canada, and Japan is thoracic radiotherapy (TRT) combined with etoposide (VePesid), either alone or in conjunction with other agents, especially a platinum agent. The specific factors related to the use of TRT in the treatment of limited SCLC are: (1) dose (total and daily), (2) volume to be irradiated, (3) fractionation, (4) timing of radiation relative to chemotherapy (concurrent, at the same time; alternating, using both within weeks; or sequential, all of one followed by all of the other without any overlap), (5) whether radiation should be given earlier or later in the treatment course, and (6) whether to use a split course (rest intervals during a course of radiotherapy) or a continuous course of radiation. This paper discusses each of these factors.
Volume
11
Issue
9 Suppl 9
First Page
31
Last Page
37
ISSN
0890-9091
Published In/Presented At
Turrisi A. T., 3rd (1997). Concurrent chemoradiotherapy for limited small-cell lung cancer. Oncology (Williston Park, N.Y.), 11(9 Suppl 9), 31–37.
Disciplines
Medicine and Health Sciences
PubMedID
9330406
Department(s)
Department of Medicine
Document Type
Article